Clinical Trials Logo

Early Parkinson Disease clinical trials

View clinical trials related to Early Parkinson Disease.

Filter by:
  • None
  • Page 1

NCT ID: NCT03655236 Active, not recruiting - Clinical trials for Early Parkinson Disease

PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706

Start date: February 18, 2019
Phase: Phase 2
Study type: Interventional

This study consists of 2 parts. Part 1 of the study is conducted to evaluate the efficacy, safety, and tolerability of two doses of K0706 compared to placebo in subjects with early Parkinson's Disease who are not receiving dopaminergic therapy. Part 2 is an optional long term extension study for subjects who have completed week 40 of Part 1

NCT ID: NCT00809302 Terminated - Clinical trials for Early Parkinson Disease

Efficacy and Safety Study of Aplindore in Patients With Early Parkinson Disease

Start date: December 2008
Phase: Phase 2
Study type: Interventional

This is a clinical trial to be conducted at multiple Parkinson Study Group (PSG) sites in the USA. Patients with early Parkinson disease will be randomly allocated to one of 4 arms in the study. The 4 arms include 3 arms with different doses of aplindore MR tablets and 1 placebo arm. The study drug will be taken twice a day (BID). The study is blinded and neither subjects, nor the investigators, will know what treatment the subject is receiving. Investigational study drug will be adjusted to the assigned dosage and then maintained at that dosage for the balance of the 12 week follow-up period. The entire study will take about 13 weeks. The study will assess the safety and tolerability of aplindore and measure how effective aplindore is in improving movement and other effects of Parkinson disease.